New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Allied Nevada Gold Corp (NYSEMKT:ANV), Geron Corporation (NASDAQ:GERN), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Zhone Technologies Inc (NASDAQ:ZHNE)
Allied Nevada Gold Corp (NYSEMKT:ANV) showed a volume of 2.53 million shares by the end of last trade whereas the average volume of the stock remained 3.40million shares. The stock opened the session at $3.87but then moved to $3.83. At that price, the stock showed a negative performance of -2.54%. Allied Nevada Gold Corp. (Allied Nevada) is a gold and silver producer focused on mining, development, and exploration of properties in the state of Nevada. The Company’s operating mine, the Hycroft Mine, is an open-pit gold and silver heap leach operation located 54 miles west of Winnemucca, Nevada. During the year ended December 31, 2012, the Hycroft Mine produced 136,930 ounces of gold and 794,097 ounces of silver. In addition to the Hycroft Mine, the Company has six properties which have reported other mineralized material and approximately 90 other early stage exploration properties.
Will ANV Get Buyers Even After The Recent Rally? Find Out Here
Geron Corporation (NASDAQ:GERN) opened the session at $4.68 and closed the session at $4.66. The stock showed a positive performance of 0.22% in previous trading session. Traded with volume of 2.49 million shares in the prior session and the average volume of the stock remained 5.41 million shares. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF),
For How Long GERN will fight for Profitability? Read This Trend Analysis report
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) opened the session at $3.35 and closed the session at $3.28. The stock showed a negative performance of -1.50% in previous trading session. Traded with volume of 2.49 million shares in the prior session and the average volume of the stock remained 3.06 million shares. The beta of the stock remained 1.36. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA).
Why Should Investors Buy AVNR After the Recent Fall? Just Go Here and Find Out
Zhone Technologies Inc (NASDAQ:ZHNE) the stock advanced 9.14% and finished the session at $5.97. Traded with volume of 2.44 million shares in the prior session and the average volume of the stock remained 789,710.00 shares. The beta of the stock remained 1.96. Zhone Technologies Inc. (Zhone) designs, develops and manufactures communications networks equipment for telecommunications, wireless and cable operators worldwide. With the Company's products and solutions, network service providers can migrate from traditional circuit-based networks to packet-based networks and from copper-based access lines to fiber-based access lines without abandoning the investments they have made in their existing infrastructures.
Will ZHNE Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)